Alice Healthcare (CEO Kang Da-gyeom) announced on the 13th that it is actively introducing its VBC response solution in the United States, marking a significant step in its global market expansion. This introduction reflects the demand from the field to objectively prove treatment outcomes with data, amid the rapid transition of the U.S. healthcare reimbursement system from Fee-for-Service (FFS) to Value-Based Care (VBC).

The U.S. healthcare system is swiftly moving from the traditional 'Fee-for-Service (FFS)' model to a 'Value-Based Care (VBC)' model. While FFS compensated based on the 'quantity (frequency)' of medical services, VBC rewards based on 'quality of treatment (outcomes)' and 'cost efficiency'.

In this VBC environment, physical therapy clinics face the challenge of proving to insurers (Payers) that "our treatment has substantially improved the patient's condition and prevented more expensive surgeries or drug treatments," demonstrating 'value'. Clinics that fail to provide objective data to prove treatment effectiveness may be excluded from insurer networks or find themselves at a disadvantage in fee negotiations.

However, the existing 'Patient-Reported Outcomes (PROs)' method, which relies on patients' subjective feelings or pain reports, has clear limitations as objective evidence of treatment effectiveness.

The 'VIVO' RTM solution directly addresses this issue with AI motion recognition technology. VIVO analyzes patients' home exercises with AI to quantify improvements in physical function, such as '15-degree increase in range of motion (ROM)' and '10-second improvement in balance retention time', into 'objective figures'. This provides decisive data that proves 'actual improvement in physical function', beyond the patients' subjective reports of 'pain reduction'.

Alice Healthcare CEO Kang Da-gyeom stated, "The massive trend in U.S. healthcare is already heading towards 'Value-Based Care', with the core of this trend being 'Measurable Outcomes'." He further emphasized, "The essence of VIVO goes beyond simple monitoring, serving as a 'data engine' that objectively measures the 'value of treatment'," adding, "VIVO will be the most powerful partner to help medical professionals prove their value and successfully adapt in the VBC era."

Popular News